Venous Thromboembolism- Market Insights & Drugs Sales Forecast (VTE) -2020

 Published On: May, 2016 |    No of Pages: 100 |  Published By: DelveInsight | Format: PDF
Request Free Sample

The Venous Thromboembolism- Market Insights & Drugs Sales Forecast (VTE) -2020 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. According to DelveInsight, Global VTE market was $4.2 billion in 2015 and expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%.

Globally the overall incidence for Venous Thromboembolism (VTE) is increasing at a higher rate. For VTE, there are approximately 1 million cases in the United States each year, many of which represent recurrent disease. The increasing epidemiology of venous thromboembolism is a key driver for the global anticoagulants market.

Key Coverage and Benefits:

• The report will help in developing business strategies by understanding the trends shaping and driving the global Venous Thromboembolism (VTE) market.
• Identifying patient populations in the global Venous Thromboembolism (VTE) market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Venous Thromboembolism (VTE) therapeutics in each of the markets covered.
• To understand the future market competition in the global Venous Thromboembolism (VTE) therapeutics market and Insightful review of the key market drivers and barriers.

Scope of the Report:

• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2015-2020.
• It also provides Venous Thromboembolism (VTE) for United States, EU5 and Japan from 2015 and forecasted Market to 2020.

Executive Summary
Market Share of Anticoagulants in 2015 and 2020
Worldwide Market Share of Anticoagulants in 2015
Worldwide Market Share of Anticoagulants in 2020
Chapter 1 Anticoagulants Introduction
Warfarin
Low Molecular Weight Heparins
New Oral Anticoagulants (NOAC)
Chapter 2 Venous Thromboembolism
Disease Overview
Epidemiology of Venous Thromboembolism
Treatment Landscape
Treatment Algorithm
Treatment Goals
Treatment Details
Chapter 3 Key Marketed Anticoagulants
Novel Oral Anticoagulants Comparison
Reversal Agents (Antidotes)
Chapter 4 Anticoagulants Market Assessment by VTE
Key Findings
Global Anticoagulants Market Sales by Venous Thromboembolism
Global Anticoagulants Market Share (%) in Venous Thromboembolism
Chapter 5 United States Anticoagulants Market Assessment
Key Findings
United States Anticoagulants Market Sales by Venous Thromboembolism
United States Anticoagulants Market Share (%) in Venous Thromboembolism
Chapter 6 Europe 5 Anticoagulants Market Assessment
Key Findings
Europe 5 Anticoagulants Market Sales by Venous Thromboembolism
Europe 5 Anticoagulants Market Share (%) in Venous Thromboembolism
Chapter 7 Japan Anticoagulants Market Assessment
Key Findings
Japan Anticoagulants Market Sales by Venous Thromboembolism
Japan Anticoagulants Market Share (%) in Venous Thromboembolism
Chapter 8 Xarelto (rivaroxaban) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Xarelto
Safety of Xarelto
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Xarelto Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Xarelto Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trials Information
SWOT Analysis of Xarelto
Chapter 9 Pradaxa (dabigatran etexilate mesylate) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Pradaxa
Safety of Pradaxa
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Pradaxa Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Pradaxa Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Pradaxa
Chapter 10 Eliquis(Apixaban) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy and Safety of Eliquis
Side effects of Eliquis
Cost of Therapy
Global Drug Sales
Eliquis Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Eliquis Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Eliquis
Chapter 11 Savaysa (edoxaban tosylate) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Savaysa
Safety of Savaysa
Side Effects of Savaysa
Cost of Therapy
Global Drug Sales
Savaysa Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Savaysa Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Savaysa
Chapter 12 Lovenox (enoxaparin) Drug Profile
Product Profile
Advantages & Disadvantages
Safety and Efficacy of Lovenox
Side effects of Lovenox
Cost of Therapy
Global Drug Sales
Lovenox Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication (20%)
Lovenox Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Lovenox
Chapter 13 Fraxiparine
Product Profile
Advantages & Disadvantages
Safety and Efficacy of Fraxiparine
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Fraxiparine Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Fraxiparine Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trials Information
SWOT Analysis of Fraxiparine
Chapter 14 Arixtra (Fondaparinux) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Arixtra
Safety of Arixtra
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Arixtra Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Arixtra Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Arixtra
Chapter 15 Betrixaban Drug Profile
Product Profile
Advantages & Disadvantages
Safety and Efficacy
Side effects of Drugs
Expected Cost of Therapy
Global Drug Sales
Betrixaban Forecasted Sales (2011-2020)
Global Drug Sales by indication
Betrixaban Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trials Information
Chapter 16 Market Drivers and Constraints
Factors Driving the Market Growth
Factors Constraining the Market Growth
Consulting Services
Disclaimer
About DelveInsight

List of Tables
Table 1 Key Marketed Anticoagulants
Table 2 Comparison of NOACs & Warfarin
Table 3 Global Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
Table 4 Global Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
Table 5 US Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
Table 6 US Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
Table 7 EU5 Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
Table 8 EU5 Anticoagulants Sales in Venous Thromboembolism – 2015-2020 (USD MM)
Table 9 Japan Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
Table 10 Japan Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
Table 11 Xarelto Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 12 Xarelto Sales by Venous Thromboembolism (VTE) (USD MM)
Table 13 Xarelto, Clinical Trials by Zone, 2016
Table 14 Pradaxa Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 15 Pradaxa Sales by Venous Thromboembolism (VTE) (USD MM)
Table 16 Pradaxa, Clinical Trials by Zone, 2016
Table 17 Eliquis Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 18 Eliquis Sales by Venous Thromboembolism (VTE) (USD MM)
Table 19 Eliquis, Clinical Trials by Zone, 2016
Table 20Savaysa Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 21 SavaysaSales by Venous Thromboembolism (VTE) (USD MM)
Table 22 Savaysa, Clinical Trials by Zone, 2016
Table 23 LovenoxHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 24 LovenoxSales by Venous Thromboembolism (VTE) (USD MM)
Table 25Lovenox, Clinical Trials by Zone, 2016
Table 26FraxiparineHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 27 FraxiparineSales by Venous Thromboembolism (VTE) (USD MM)
Table 28Fraxiparine, Clinical Trials by Zone, 2016
Table 29 ArixtraHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 30 ArixtraSales by Venous Thromboembolism (VTE) (USD MM)
Table 31Arixtra, Clinical Trials by Zone, 2016
Table 32BetrixabanForecasted Sales (2011-2020)(USD MM)
Table 33 BetrixabanSales by Venous Thromboembolism (VTE) (USD MM)
Table 34Betrixaban, Clinical Trials by Zone, 2016

List of Figures
Figure 1 Global Anticoagulants Sales in Venous Thromboembolism- 2011-2020
Figure 2 Global Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
Figure 3 US Anticoagulants Sales in Venous Thromboembolism- 2011-2020
Figure 4 US Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
Figure 5 EU5 Anticoagulants Sales in Venous Thromboembolism- 2011-2020
Figure 6 EU5 Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
Figure 7 Japan Anticoagulants Sales in Venous Thromboembolism- 2011-2020
Figure 8 Japan Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
Figure 9 Xarelto Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 10 Xarelto Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 11 Xarelto, Clinical Trials by Zone (%), 2016
Figure 12 Pradaxa Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 13 Pradaxa Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 14 Pradaxa, Clinical Trials by Zone (%), 2016
Figure 15 Eliquis Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 16 Eliquis Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 17 Eliquis, Clinical Trials by Zone (%), 2016
Figure 18 SavaysaHistorical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 19 Savaysa Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 20 Savaysa, Clinical Trials by Zone (%), 2016
Figure 21 Lovenox Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 22 Lovenox Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 23 Lovenox, Clinical Trials by Zone (%), 2016
Figure 24 Fraxiparine Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 25 Fraxiparine Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 26 Fraxiparine, Clinical Trials by Zone (%), 2016
Figure 27 ArixtraHistorical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 28 Arixtra Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 29 Arixtra, Clinical Trials by Zone (%), 2016
Figure 30 BetrixabanForecasted Sales (2011-2020) (USD MM)
Figure 31 Betrixaban Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 32 Betrixaban, Clinical Trials by Zone (%), 2016


If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.